This trial is testing whether the study drug ruxolitinib can help hair regrowth in people with APECED-associated AA and if it can improve other symptoms caused by the immune system's attack to the body.
- Alopecia Areata
- Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy (APECED)
1 Primary · 34 Secondary · Reporting Duration: Week 32
Side Effects for
1 Treatment Group
1 of 1
70 Total Participants · 1 Treatment Group
Primary Treatment: Ruxolitinib · No Placebo Group · Phase 2
Who is running the clinical trial?
Age 12 - 65 · All Participants · 17 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
|National Institutes of Health Clinical Center||100.0%|
What portion of applicants met pre-screening criteria?
How responsive is this trial?
Typically responds via
Most responsive sites:
- National Institutes of Health Clinical Center: < 48 hours
Average response time
- < 2 Days
Frequently Asked Questions
Is it possible for me to participate in this experiment?
"This trial seeks 70 participants suffering from alopecia areata, between the ages of 12 and 65 to be included." - Anonymous Online Contributor
Is enrollment for this research endeavor currently available?
"Data on clinicaltrials.gov verifies that this trial, first posted on December 1st 2022, is actively seeking participants. The information concerning the experiment was recently amended on November 25th of the same year." - Anonymous Online Contributor
Is Ruxolitinib a viable therapeutic option with minimal risk?
"Due to its Phase 2 status, there is some evidence of Ruxolitinib's safety but no data attesting to the efficacy. Consequently, a score of two was assigned on our team at Power's scale from 1-3." - Anonymous Online Contributor
Does this trial permit individuals under the age of fifty to participate?
"The required age range for this particular experiment is between 12 and 65 years old. Meanwhile, there are 10 trials aimed at minors and 79 focusing on individuals over the retirement age." - Anonymous Online Contributor
What is the maximum number of participants this clinical trial can accommodate?
"Affirmative. The clinicaltrials.gov website confirms that this medical trial, which was first published on December 1st 2022, is currently recruiting patients from one location and needs to find 70 participants in total." - Anonymous Online Contributor